Cargando…
CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
Targeting cancer cells using chimeric-antigen-receptor (CAR-)T cells has propelled adoptive T-cell therapy (ATT) to the next level. A plentitude of durable complete responses using CD19-specific CAR-T cells in patients suffering from various lymphoid malignancies resulted in the approval by the food...
Autores principales: | Harrer, Dennis C., Dörrie, Jan, Schaft, Niels |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928974/ https://www.ncbi.nlm.nih.gov/pubmed/31779130 http://dx.doi.org/10.3390/ijms20235942 |
Ejemplares similares
-
Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022) -
CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019) -
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023) -
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019) -
CARs: Beyond T Cells and T Cell-Derived Signaling Domains
por: Sievers, Nico M., et al.
Publicado: (2020)